Argenx’s Vyvgart: Driving Growth and Strategic Expansion with Strong Buy Rating

William Blair analyst Myles Minter has maintained their bullish stance on ARGX stock, giving a Buy rating on March 13.

Myles Minter has given his Buy rating due to a combination of factors, primarily focusing on the promising prospects of Argenx’s flagship product, Vyvgart. Vyvgart, an FcRn inhibitor, has been approved for treating AChR autoantibody positive generalized myasthenia gravis (gMG) and is being explored for other neuromuscular disorders. The drug has demonstrated significant commercial success since its launch, showcasing robust quarter-over-quarter growth.
Minter’s confidence is further bolstered by insights from experts like Dr. Chafic Karam, who provides valuable perspectives on Vyvgart’s real-world application and its competitive positioning in the treatment landscape. Additionally, the potential approval of Vyvgart’s prefilled syringe formulation, which could allow for self-administration, represents a strategic expansion opportunity for Argenx. These factors collectively contribute to Minter’s positive outlook on Argenx’s stock performance.

In another report released on March 13, TD Cowen also maintained a Buy rating on the stock with a $761.00 price target.